首页> 外文期刊>Breast cancer research and treatment. >MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2)
【24h】

MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2)

机译:MiR-181a通过靶向乳腺癌抗性蛋白(BCRP / ABCG2)来增强抗米托蒽醌的乳腺癌细胞的药物敏感性

获取原文
获取原文并翻译 | 示例
           

摘要

Breast cancer resistance protein (BCRP)/ATP-binding cassette subfamily G member 2 (ABCG2) mediates multidrug resistance (MDR) in breast cancers. In this study, we aimed to investigate the role of microRNAs in regulation of BCRP expression and BCRP-mediated drug resistance in breast cancer cells. Microarray analysis was performed to determine the differential expression patterns of miRNAs that target BCRP between the MX-resistant breast cancer cell line MCF-7/MX and its parental MX-sensitive cell line MCF-7. MiR-181a was found to be the most significantly down-regulated miRNA in MCF-7/MX cells. Luciferase activity assay showed that miR-181a mimics inhibited BCRP expression by targeting the 3′ untranslated region (UTR) of the BCRP mRNA. Overexpression of miR-181a down-regulated BCRP expression, and sensitized MX-resistant MCF-7/MX cells to MX. In a nude mouse xenograft model, intratumoral injection of miR-181a mimics inhibited BCRP expression, and enhanced the antitumor activity of MX. In addition, miR-181a inhibitors up-regulated BCRP expression, and rendered MX-sensitive MCF-7 cells resistant to MX. These findings suggest that miR-181a regulates BCRP expression via binding to the 3′-UTR of BCRP mRNA. MiR-181a is critical for regulation of BCRP-mediated resistance to MX. MiR-181a may be a potential target for preventing and reversing drug resistance in breast cancer.
机译:乳腺癌抗性蛋白(BCRP)/ ATP结合盒亚家族G成员2(ABCG2)介导乳腺癌的多药耐药性(MDR)。在这项研究中,我们旨在研究microRNA在乳腺癌细胞中BCRP表达和BCRP介导的耐药性调控中的作用。进行微阵列分析以确定靶向MX耐药的乳腺癌细胞系MCF-7 / MX与其亲代MX敏感细胞系MCF-7之间的BCRP的miRNA的差异表达模式。发现MiR-181a是MCF-7 / MX细胞中最显着下调的miRNA。荧光素酶活性测定表明,miR-181a模拟物通过靶向BCRP mRNA的3'非翻译区(UTR)来抑制BCRP表达。 miR-181a的过表达下调了BCRP表达,并使耐MX的MCF-7 / MX细胞对MX敏感。在裸鼠异种移植模型中,miR-181a模拟物的肿瘤内注射抑制了BCRP表达,并增强了MX的抗肿瘤活性。此外,miR-181a抑制剂上调BCRP表达,并使MX敏感的MCF-7细胞对MX具有抗性。这些发现表明,miR-181a通过与BCRP mRNA的3'-UTR结合来调节BCRP表达。 MiR-181a对于调节BCRP介导的MX抗性至关重要。 MiR-181a可能是预防和逆转乳腺癌耐药性的潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号